Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
P/E ratio for Evoke Pharma, Inc. (EVOK)
P/E ratio as of 2023: -5.41
According to Evoke Pharma, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.41. At the end of 2022 the company had a P/E ratio of -12.39.
P/E ratio history for Evoke Pharma, Inc. from 2011 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -5.41 |
| 2022 | -12.39 |
| 2021 | -23.53 |
| 2020 | -59.54 |
| 2019 | -61.10 |
| 2018 | -65.33 |
| 2017 | -33.05 |
| 2016 | -21.07 |
| 2015 | -21.20 |
| 2014 | -32.25 |
| 2013 | -74.66 |
| 2012 | -78.52 |
| 2011 | -66.63 |